Myriad Genetics is a molecular diagnostic company that develops and markets predictive medicine, personalized medicine and prognostic medicine tests. Co.'s commercial molecular diagnostic tests are BRACAnalysis® test for breast and ovarian cancer, BRACAnalysis Large Rearrangement Test also for breast and ovarian cancer, COLARIS® test for colorectal cancer and uterine cancer, COLARIS AP® test for colorectal cancer, MELARIS ® test for melanoma, PANEXIA™ test for pancreatic cancer, PREZEON® immunohistochemistry test for cancer, Prolaris® test for prostate cancer, and TheraGuide® 5-FU test for drug toxicity.
MYGN — Key Stats (updated Monday, March 3, 10:24 AM)
Nothing in ETF Channel is intended to be investment advice, nor does it represent the opinion of, counsel
from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners.
None of the information contained herein constitutes a recommendation that any particular security, portfolio,
transaction, or investment strategy is suitable for any specific person. All viewers agree that under no
circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held
liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you
agree to the following Full Disclaimer & Terms of Service. Video widget and ETF videos powered by Market News Video. Quote data delayed at least 20
minutes; ETF data powered by Ticker Technologies, and Mergent. Contact ETF Channel; Meet Our Editorial Staff.